VEGF plasma levels reduced after bevacizumab injection for DME, AMD

TORONTO — There was significant reduction of vascular endothelial growth factor plasma levels at 1 and 4 weeks after bevacizumab injection in patients with age-related macular degeneration and in patients with diabetic macular edema, a presenter said here. However, no change in plasma VEGF level was seen after intravitreal injection of Lucentis (ranibizumab, Genentech) or Macugen (pegaptanib, Valeant), according to Gerhard Kieselbach, MD, who presented study findings at the American Society of Retina Specialists meeting.

Full Story →